Tom Bishop: But in the final data?
Christopher Missling: It might be done in several different slices of papers, because papers have a limited number of data points and number of words you can include. So the first paper will be the full data of the main items of the endpoints and then additional endpoints might be separately published.
Tom Bishop: What about Australia?
Christopher Missling: What about Australia?
Tom Bishop: Yes, approval.
Christopher Missling: So the — again, as I mentioned before, the most time consuming, lengthy, because it’s a very structured process with deadlines is the European application and that’s why we went there first and also because that patients were mostly or partially in Europe as for that reason we started the process there. But the main reason was really that the process for application takes the longest in Europe, so it’s the first we started with and the international other applications will subsequently proceed.
Tom Bishop: Okay, the Parkinson’s data has been in the wings for a long time. What’s the delay?
Christopher Missling: What Parkinson data, please?
Tom Bishop: The Parkinson’s next trial.
Christopher Missling: The initiation of the trial? Yes. So we had several very productive interactions with K Wealth and we were able to fine tune the protocol to maximize this protocol to make it really crystal clear and easy to adhere to, but also make it meaningful for future application. And that’s why we ended up doing it so, so properly and you will get the news eventually that when we have the first patients dosed. So we proceed with that indication.
Tom Bishop: The enrollment of the 96 trial? The status?
Christopher Missling: The majority of the patients from the 96 ATTENTION-AD trials were derived from the Alzheimer Phase 2b/3 study. And they all came from the Alzheimer Phase 2b/3 study. That’s the correct way to put it. And we had extremely high rollover from the double-blind, placebo-controlled into the open-label ATTENTION-AD study. I think it was over 90%. And we have a large number of patients on this study. We even have the first patients who finished that study going over and requesting an extension of this extension by another year. So it became now a 144 week study for some patients. And thereafter, we also have patients which requested to be given the drug continuously, and we provided them the drug on compassionate use. So there’s a high request for patients to stay on the study drug.
Tom Bishop: Thank you. Sorry for the echo.
Christopher Missling: No problem.
Clint Tomlinson: That’s okay, Tom. So I believe that’s the end of the call. We have no further questions at this time. Dr. Missling.
Christopher Missling: Thank you. So again, this is an exciting time for the company and we’re very excited to be entering a new phase of the company’s history with our biomarker driven precision medicine programs in addressing significant unmet medical needs and economic burden. We remain very focused on execution as we prepare for the year ahead of us. Thank you very much.
Clint Tomlinson: Thank you, ladies and gentlemen. This concludes today’s conference call, and we appreciate you participating. You may now disconnect.
